Can you get disability benefits for ALS? 3 things to do if your claim is denied
If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...
The Pharma Letter2h
New CEO to advance VectorY’s ALS therapy VTx-002
VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...
Muscular Dystrophy Association Announces Over $5 Million in Research Grants to Advance Neuromuscular Disease Research
Research Grants and 7 Development Awards for Fellowship Trainees Will Fund Critical Research Across Multiple Neuromuscular ...
Business Wire2h
VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces ...
STAT2d
They agreed to cover a drug for six months — and now I have to fight for it again
Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...
Private Medicare plans must cover Biogen's ALS drug, US agency says
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...
Hosted on MSN3d
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...
FierceBiotech4d
Corcept's cortisol modulator fails to slow ALS decline, linked to 'gastrointestinal upset' at onset
Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...